Submit Your Feeds

Business News • PR NewsWire • Relapsing MS patients more satisfied with Novartis oral drug Gilenya® than standard injectable therapies, according to new study results at CMSC

Relapsing MS patients more satisfied with Novartis oral drug Gilenya® than standard injectable therapies, according to new study results at CMSC
Relapsing MS patients more satisfied with Novartis oral drug Gilenya® than standard injectable therapies, according to new study results at CMSC

EAST HANOVER, N.J., May 30, 2013 /PRNewswire/ -- People with relapsing multiple sclerosis (MS) reported greater treatment satisfaction after starting the oral treatment Gilenya® (fingolimod) vs. switching to, or staying on, injectable interferon beta or glatiramer acetate,...

View More : http://www.prnewswire.com/news-releases/relapsing-ms-patients-more-satisfied-with-novartis-oral-drug-gilenya-than-standa...
Releted News by prnewswire
L'IMD publie la 25ème édition de son classement sur la compétitivité mondiale
La scuola di business IMD pubblica la 25esima edizione della classifica di competitività mondiale
Relapsing MS patients more satisfied with Novartis oral drug Gilenya® than standard injectable therapies, according to new study results at CMSC
Home Sitemap Contact Us
© businessNewsNewsNews.com